Skip to main content

About Takeda

About Takeda Ventures, Inc.

TVI's mission is to identify, help create and support the development of therapeutic innovation that aligns with Takeda’s own strategic imperatives. We do this by investing in technology and product concepts, and highly effective teams that can turn ideas into reality. Our primary focus is on medium to longer term returns in the form of product and technology successes for our portfolio companies and capital gains for the financial institutions we work with. As a Pharma strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts from preclinical through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources.

TVI is based in Palo Alto, California and is actively seeking global investment opportunities. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on cardiometabolic, central nervous system, chronic inflammatory and immune modulation, and oncology therapeutic domains. Our focus also includes gastroenterology and renal/urological diseases, as well as innovative platforms for drug target and biomarker identification, regenerative medicines, innovative vaccines technologies and delivery systems for novel protein and peptide therapeutics.

TVI currently does not invest in diagnostics platforms, medical technology and devices or anti-infective products.

About Takeda Pharmaceutical Company, Ltd.

Takeda Pharmaceutical Company, Ltd. (TPC) is a research-based, global company with its main focus on the discovery and development of ethical pharmaceuticals. It is the largest pharmaceutical company in Japan and among the largest in the world. TPC is committed to striving toward better health for individuals and progress of medicine. It does this directly though its own organic discovery and development efforts and also through collaborations. Among the company's most notable successes to date are Actos®, Prevacid® (Takepron®), Lupron® (Enantone®), Blopress® (Atacand®) and Velcade®.

TPC takes pride in its highly regarded discovery research capabilities which continue to fuel an innovative pipeline of drug candidates in areas where the medical need remains high. Through judicious investment in high-caliber biopharmaceutical and technology-based ventures, TVI aims to further increase the depth and breadth of these capabilities and ensure that Takeda remains a major force in the drive to improve global human healthcare.